Vertex Pharmaceuticals

Corporate brand

American biopharmaceutical company known for disease-modifying cystic fibrosis medicines and emerging genetic, cell and non-opioid pain therapies.

Last updated August 27, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Vertex Pharmaceuticals is a Boston-based American biopharmaceutical company that develops and commercializes medicines for serious diseases, particularly conditions with a strong genetic or molecular basis. Founded in 1989 by Joshua Boger and Kevin J. Kinsella, the company was established around the idea that rational drug design and a close understanding of disease biology could improve the treatment of disorders that had previously been managed mainly through symptoms. Its early research covered viral infections, inflammatory and autoimmune disease, and cancer, but its most important commercial and scientific franchise became cystic fibrosis (CF). Vertex's CF strategy focused on correcting the defective CFTR protein rather than treating only the pulmonary and digestive consequences of the disease. This work produced ivacaftor, marketed as Kalydeco, which received United States approval in 2012 for eligible patients with specific CFTR mutations. It was among the first medicines to address the underlying molecular cause of CF in a defined genetic population. Vertex subsequently developed combination regimens including Orkambi, Symdeko and the triple combination elexacaftor/tezacaftor/ivacaftor, marketed in the United States as Trikafta and in some other markets as Kaftrio. The triple therapy, approved by the U.S. Food and Drug Administration in 2019, expanded treatment to patients representing a large majority of the CF population and became the company's leading product franchise. The company has used partnerships, acquisitions and internal research to broaden beyond CF. Its collaboration with CRISPR Therapeutics led to exagamglogene autotemcel, formerly known as CTX001, a gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia. Vertex later acquired Semma Therapeutics and ViaCyte to strengthen its work on stem-cell-derived replacement beta cells for type 1 diabetes. Other research programs have addressed Duchenne muscular dystrophy, myotonic dystrophy type 1, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease and pain. In 2025, the FDA approved Journavx, or suzetrigine, an oral non-opioid treatment for moderate to severe acute pain in adults. The approval marked Vertex's entry into a large market outside rare genetic disease and represented the first U.S. approval in roughly 25 years for a new class of non-opioid acute pain medicine. Vertex remains positioned as a research-led innovator whose business depends on specialized medicines, genetic medicine platforms and premium pricing supported by clinical differentiation. Vertex maintains its corporate headquarters in Boston and research facilities in San Diego and Milton Park, Oxfordshire. It is listed on the Nasdaq under the ticker VRTX. The company's success has also generated sustained debate about the price and international availability of its CF medicines, particularly in the United Kingdom and lower-income countries. Access negotiations with public health systems have expanded over time, but reimbursement, affordability and the use of intellectual-property protections remain prominent issues surrounding the brand.

History

Vertex Pharmaceuticals was founded in 1989 by Joshua Boger and Kevin J. Kinsella with an explicit ambition to change how serious diseases were treated. Unlike biotechnology approaches centered primarily on combinatorial chemistry, Vertex emphasized rational drug design: identifying disease mechanisms, selecting molecular targets and designing compounds intended to alter those mechanisms. The company's early scientific and commercial development was later chronicled in Barry Werth's books The Billion-Dollar Molecule and The Antidote. During its first decade and a half, Vertex explored treatments for viral infections, inflammatory and autoimmune disorders, and cancer. Its most consequential program emerged from work on cystic fibrosis, a genetic disease caused by mutations affecting the CFTR protein. The Cystic Fibrosis Foundation provided substantial support through a venture-philanthropy model, ultimately investing approximately $150 million in Vertex-related development. That partnership helped sustain a long research program and contributed to the development of ivacaftor. In January 2012, the FDA approved Kalydeco for patients with a specific CFTR mutation. The medicine was important because it treated the molecular defect underlying CF rather than only its downstream symptoms. Vertex then pursued combinations designed to address the common F508del mutation. Orkambi, combining lumacaftor and ivacaftor, received U.S. approval in 2015, and Symdeko, combining tezacaftor and ivacaftor, followed in 2018. In October 2019, the FDA approved Trikafta, a triple CFTR-modulator regimen that made treatment available to a much broader share of the CF population. Vertex expanded its physical and organizational footprint as its CF business grew. It moved its headquarters from Cambridge to a new South Boston waterfront complex in 2014. The company also maintained research operations in San Diego and Milton Park in Oxfordshire. Its employee count grew from roughly 1,800 in 2009 to approximately 2,500 in 2019, according to the cited historical material. The company began diversifying its pipeline through collaborations and acquisitions. In 2015 it partnered with CRISPR Therapeutics on gene-editing treatments for inherited blood disorders. That work led to CTX001, later developed as exagamglogene autotemcel and marketed as Casgevy, for sickle cell disease and transfusion-dependent beta thalassemia. Vertex also collaborated with Moderna on messenger-RNA approaches for cystic fibrosis and with Arbor Biotechnologies on gene-editing technologies. Its acquisition of Exonics Therapeutics in 2019 supported programs in Duchenne muscular dystrophy and myotonic dystrophy type 1. The acquisition of Semma Therapeutics in 2019 and ViaCyte in 2022 expanded its efforts to create implantable or otherwise deliverable replacement beta cells for type 1 diabetes. Leadership changed in April 2020, when Reshma Kewalramani, previously the company's chief medical officer, became president and chief executive officer. Jeffrey Leiden, who had led Vertex as CEO, became executive chairman. Vertex later agreed to acquire Alpine Immune Sciences in 2024, adding another platform for immune-mediated disease research. Vertex also developed and commercialized medicines outside cystic fibrosis. Its hepatitis C protease inhibitor telaprevir, marketed as Incivek, was approved in 2011 but discontinued in 2014. The company's most significant newer non-CF launch was Journavx, an oral non-opioid acute pain medicine approved by the FDA in 2025. This broadened Vertex's commercial identity from a specialist CF company into a diversified biotechnology and pharmaceutical business focused on genetically informed medicines, cell therapies and differentiated treatments. Pricing and access have remained central to public discussion of Vertex. Annual prices for its CF medicines have been criticized by patients, physicians, advocacy groups and health systems, especially in the United Kingdom. Negotiations with the NHS involved Orkambi and other CF medicines, and expired packs were reportedly destroyed during the 2019 negotiations. NHS England reached a wider funding agreement with Vertex in October 2019, later extending it to include Kaftrio. NICE's 2023 position concerning the cost of certain Vertex CF medicines was followed by an agreement in 2024 that extended the existing pricing arrangement. International access has expanded, but availability and reimbursement remain uneven, especially in lower-income regions.

2025
Journavx is approved for acute pain
[3]FDA approval of Journavxfda.gov
The FDA approves suzetrigine, an oral non-opioid treatment for moderate to severe acute pain in adults.
2022
ViaCyte acquisition expands cell-therapy work
[1]Vertex Pharmaceuticalsen.wikipedia.org
Vertex acquires ViaCyte to advance stem-cell-derived cell replacement for type 1 diabetes.
2020
Reshma Kewalramani becomes CEO
[1]Vertex Pharmaceuticalsen.wikipedia.org
Kewalramani succeeds Jeffrey Leiden as president and chief executive officer.
2019
Trikafta is approved
[1]Vertex Pharmaceuticalsen.wikipedia.org
The triple CFTR-modulator regimen receives FDA approval and substantially broadens the treatable CF population.
2015
Vertex begins CRISPR collaboration
[1]Vertex Pharmaceuticalsen.wikipedia.org
Vertex and CRISPR Therapeutics begin developing gene-edited treatments for inherited diseases.
2014
Vertex completes move to Boston headquarters
[1]Vertex Pharmaceuticalsen.wikipedia.org
The company consolidates its Greater Boston workforce in a new South Boston waterfront complex.
2012
Kalydeco is approved
[1]Vertex Pharmaceuticalsen.wikipedia.org
Ivacaftor becomes the first Vertex CF medicine approved to treat the underlying defect for patients with a qualifying mutation.
2011
Incivek receives U.S. approval
[1]Vertex Pharmaceuticalsen.wikipedia.org
The hepatitis C protease inhibitor telaprevir is approved and commercialized with regional partners.
1989
Vertex is founded
[1]Vertex Pharmaceuticalsen.wikipedia.org
Joshua Boger and Kevin J. Kinsella establish Vertex around rational drug design and a mission to improve treatment for serious disease.

Products and positioning

Research-led, high-value innovative therapies for serious and genetically defined diseases

Cystic fibrosis CFTR modulator · 2012
Kalydeco
Kalydeco is the brand name for ivacaftor, a small-molecule CFTR potentiator. It was Vertex's first approved medicine for cystic fibrosis and is used in patients whose mutations produce a CFTR channel that can be improved by potentiation. Its significance lies in treating a defined molecular cause of CF rather than addressing only infection, inflammation or airway obstruction.
Cystic fibrosis CFTR combination · 2015
Orkambi
Orkambi combines lumacaftor and ivacaftor. Lumacaftor helps increase the amount of functional CFTR protein reaching the cell surface, while ivacaftor improves channel activity. The regimen was developed for patients with two copies of the F508del CFTR mutation and extended Vertex's mutation-specific treatment strategy beyond Kalydeco.
Cystic fibrosis CFTR combination · 2018
Symdeko
Symdeko combines tezacaftor and ivacaftor. It was designed to improve CFTR processing and activity for additional groups of patients with qualifying mutations. The product formed an intermediate step between earlier dual therapy and Vertex's later triple-combination regimen.
Cystic fibrosis CFTR triple combination · 2019
Trikafta/Kaftrio
Trikafta, called Kaftrio in several markets, contains elexacaftor, tezacaftor and ivacaftor. The combination addresses different stages of CFTR protein production and channel function. Its 2019 U.S. approval represented a major expansion of Vertex's CF franchise because it applied to patients with at least one F508del mutation and covered approximately 90% of the U.S. CF population.
Gene-edited cell therapy · 2023
Casgevy
Casgevy is the commercial name associated with exagamglogene autotemcel, a CRISPR-based autologous cell therapy developed by Vertex with CRISPR Therapeutics. The treatment uses a patient's hematopoietic stem cells, edits them outside the body and reinfuses them after conditioning. It targets severe inherited blood disorders including sickle cell disease and transfusion-dependent beta thalassemia.
Non-opioid acute pain medicine · 2025
Journavx
Journavx is the brand name for suzetrigine, an oral non-opioid medicine for moderate to severe acute pain in adults. It acts through a peripheral pain-signaling pathway rather than the opioid receptor system. Its approval broadened Vertex's product portfolio into acute pain and gave the company a potential alternative to opioid-based analgesia for appropriate patients.

Controversies

2019
Expired Orkambi packs destroyed during NHS negotiations
Vertex was reported to have destroyed 7,880 packs of Orkambi after they expired during negotiations with the UK's National Health Service, intensifying public criticism of the access dispute.
Source
2019
Access and generic-competition criticism over Trikafta
Advocacy groups and commentators criticized Vertex's international availability policies and efforts to protect its intellectual-property position, arguing that patients in lower-income countries faced limited access.
Source
2015
Criticism of cystic fibrosis medicine pricing
Physicians, patient advocates and commentators criticized the prices of Vertex's CF medicines, arguing that high annual costs could restrict access despite the medicines' clinical value.
Source

2019United Kingdom cystic fibrosis access negotiations
United Kingdom
Patient groups and health authorities pressed Vertex over the cost and reimbursement terms for Orkambi and related CF medicines.
Outcome. NHS England reached a wider funding agreement in October 2019, with later arrangements covering additional medicines and future indications.
Source
1990Cystic fibrosis venture-philanthropy development partnership
United States
The Cystic Fibrosis Foundation provided major development support and investment to Vertex, helping fund the long research program that led to Kalydeco.
Outcome. The partnership contributed to the development of a disease-modifying CF medicine and became a prominent example of venture philanthropy in drug development.
Source

Brand decisions

2024
Acquire Alpine Immune SciencesM&A
Background
Vertex sought additional immune-engineering and clinical-stage capabilities.
Action taken
Vertex agreed to acquire Alpine Immune Sciences for approximately $4.9 billion.
Aftermath
The transaction broadened Vertex's platform beyond cystic fibrosis and genetic medicines.
Transaction value. $4.9 billion (2024)
Source
2022
Acquire ViaCyteM&A
Background
Vertex aimed to accelerate development of stem-cell-derived cell replacement therapies for type 1 diabetes.
Action taken
Vertex announced the acquisition of ViaCyte for $320 million.
Aftermath
ViaCyte's cell-therapy technology was combined with Vertex's diabetes research program.
Acquisition price. $320 million (2022)
Source
2019
Acquire Exonics TherapeuticsM&A
Background
Vertex sought to expand its genetic-medicine pipeline into Duchenne muscular dystrophy and myotonic dystrophy type 1.
Action taken
Vertex announced an acquisition valued at up to $1 billion and continued a collaboration with CRISPR Therapeutics.
Aftermath
The transaction strengthened Vertex's early-stage genetic disease research portfolio.
Potential transaction value. Up to $1 billion (2019)
Source
2019
Acquire Semma TherapeuticsM&A
Background
Vertex wanted to develop replacement beta-cell treatments for type 1 diabetes.
Action taken
Vertex agreed to acquire Semma Therapeutics for $950 million in cash.
Aftermath
The deal added stem-cell-derived beta-cell and implantable-device capabilities to Vertex's pipeline.
Acquisition price. $950 million (2019)
Source

Recent events

2025
FDA approves Journavx for acute pain[3]FDA approval of Journavxfda.gov
Product launch
Suzetrigine became the first U.S.-approved medicine in a new non-opioid acute pain class in approximately 25 years.
2024
Vertex agrees to acquire Alpine Immune Sciences[4]Vertex acquisition of Alpine Immune Sciencesnews.vrtx.com
M&A
Vertex announced an agreement to acquire the Seattle clinical-stage biotechnology company, adding its immunology and protein-engineering capabilities.
2022
Vertex agrees to acquire ViaCyte[1]Vertex Pharmaceuticalsen.wikipedia.org
M&A
The acquisition strengthened Vertex's stem-cell-derived cell replacement program for type 1 diabetes.
2020
Vertex changes chief executive leadership[1]Vertex Pharmaceuticalsen.wikipedia.org
Leadership change
Reshma Kewalramani became president and CEO, while Jeffrey Leiden moved to executive chairman.
2019
FDA approves Trikafta[1]Vertex Pharmaceuticalsen.wikipedia.org
Product launch · Product generation
The elexacaftor/tezacaftor/ivacaftor triple combination was approved for patients aged 12 and older with at least one F508del mutation, covering approximately 90% of people with CF in the United States.
2019
Vertex announces acquisition of Semma Therapeutics[1]Vertex Pharmaceuticalsen.wikipedia.org
M&A
Vertex agreed to acquire the stem-cell company to advance replacement beta-cell approaches for type 1 diabetes.
2019
Vertex executive Ian Smith is terminated[1]Vertex Pharmaceuticalsen.wikipedia.org
Leadership change · Other
The company's COO and interim CFO was dismissed after Vertex said undisclosed personal behavior violated its code of conduct.
2018
FDA approves Symdeko[1]Vertex Pharmaceuticalsen.wikipedia.org
Product launch
Tezacaftor/ivacaftor expanded Vertex's CFTR-modulator portfolio for additional mutation groups.
2015
FDA approves Orkambi[1]Vertex Pharmaceuticalsen.wikipedia.org
Product launch
The lumacaftor/ivacaftor combination was approved for eligible patients with two copies of the F508del mutation.
2012
FDA approves Kalydeco for a cause-targeting cystic fibrosis treatment[1]Vertex Pharmaceuticalsen.wikipedia.org
Product launch · Product generation
Vertex received U.S. approval for ivacaftor in patients with qualifying CFTR mutations, establishing its disease-modifying cystic fibrosis franchise.

Sources9 sources

Cite this profile: Cite the canonical profile. /brand-wiki/vertex-pharmaceuticals · Editorial policy · How profiles are compiled